Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer

被引:0
|
作者
Serrano, Mariana [1 ]
Araujo, Jhajaira M. [2 ]
Pacheco, Cristian [1 ]
Macetas, Jackeline [1 ]
Blum, Mariella A. [3 ]
Carrato, Alfredo [4 ]
Ruiz, Eloy [5 ]
Berrospi, Francisco [5 ]
Luque, Carlos [5 ]
Chavez, Ivan [5 ]
Payet, Eduardo [1 ]
Taxa, Luis [6 ]
Montenegro, Paola [1 ]
机构
[1] Inst Nacl Enfermedades Neoplas, Dept Med Oncol, Lima 15038, Peru
[2] Univ Privada San Juan Bautista, Escuela Profes Med Humana, Lima 15067, Peru
[3] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[4] Hosp Ramon & Cajal, Dept Med Oncol, E-28034 Madrid, Spain
[5] Inst Nacl Enfermedades Neoplas, Dept Cirugia Abdomen, Lima 15038, Peru
[6] Inst Nacl Enfermedades Neoplas, Dept Patol, Lima 15038, Peru
来源
ECANCERMEDICALSCIENCE | 2022年 / 16卷
关键词
gastric cancer; adjuvant chemotherapy; survival; ELDERLY-PATIENTS; RECURRENCE; RATIO; CARCINOMA; RESECTION; PATTERNS; SURGERY; ALBUMIN; IMPACT;
D O I
10.3332/ecancer.2022.1387
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Gastric cancer (GC) is the fourth most common cause of cancer deaths around the world and the first cause of cancer deaths in Peru; however, there are no prospective trials for adjuvant chemotherapy in GC after curative gastrectomy in this country. The objective of this study was to evaluate the effectiveness of adjuvant chemotherapy in stage II-III gastric cancer patients who underwent D2 gastrectomy. Methods: We included patients with stage II-III gastric cancer who underwent radical gastrectomy and D2 dissection between 2014 and 2016 at our institution. Patients received 3-week cycles of capecitabine (1,000 mg/m(2) twice daily on days 1-14) plus oxaliplatin (130 mg/m(2) on day 1) for 6 months. Survival curves were estimated with the Kaplan-Meier method, and the Cox proportional hazards model was used to identify prognostic factors for survival. Results: In total, 173 patients were included: 100 (57.8%) patients received adjuvant chemotherapy and surgery (AChS) and 73 (42.2%) surgery alone (SA). Three-year disease-free survival (DFS) was higher in the AChS groups (69%) than in the SA group (52.6%) (p = 0.034). Regarding overall survival (OS), 31 patients (31%) died in the AChS group compared with 34 (46.6%) in the SA group (p = 0.027). In the multivariate analysis, adjuvant chemotherapy was an independent prognostic factor for DFS (HR = 0.60; 95% CI = 0.37-0.97; p = 0.036) and OS (HR = 0.58; 95% CI = 0.36-0.95; p = 0.029). ACh showed consistent benefit in DFS and OS for patients with albumin >3.5 g/dL, lymphovascular and perineural invasion, pT4, pN2-3, pathologic stage (PS) IIIA and IIIB and lymph node ratio (LNR) > 13.1. Conclusion: These data suggest that adjuvant capecitabine and oxaliplatin reduce the recurrence and mortality in patients with stage II-III gastric cancer who underwent D2 gastrectomy. PS IIIA and IIIB and LNR > 13.1 benefited more from receiving adjuvant chemotherapy and poorly cohesive gastric carcinoma did not significantly reduce the rates of survival.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Adjuvant chemotherapy after D2 gastrectomy for gastric cancer
    Takaki Yoshikawa
    Mitsuru Sasako
    [J]. Nature Reviews Clinical Oncology, 2012, 9 : 192 - 194
  • [2] Adjuvant Chemotherapy for Elderly Patients with Gastric Cancer after D2 Gastrectomy
    Jin, Ying
    Qiu, Miao-zhen
    Wang, De-shen
    Zhang, Dong-sheng
    Ren, Chao
    Bai, Long
    Luo, Hui-yan
    Wang, Zhi-qiang
    Wang, Feng-hua
    Li, Yu-hong
    Xu, Rui-hua
    [J]. PLOS ONE, 2013, 8 (01):
  • [3] GASTROINTESTINAL CANCER Adjuvant chemotherapy after D2 gastrectomy for gastric cancer
    Yoshikawa, Takaki
    Sasako, Mitsuru
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (04) : 192 - 194
  • [4] Adjuvant therapy for gastric cancer after D2 gastrectomy
    Nishida, Toshirou
    [J]. LANCET, 2012, 379 (9813): : 291 - 292
  • [5] Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
    Yu, Shan
    Wang, Yan
    Cheng, Xi
    Lv, Minzhi
    Cui, Yuehong
    Li, Wei
    Yu, Yiyi
    Li, Qian
    Liu, Tianshu
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 10091 - 10101
  • [6] Is There a Benefit for Added Radiation to Adjuvant Chemotherapy after D2 Gastrectomy for Resectable Gastric Cancer?
    Jalfon, Michael J.
    Tsao, Miriam
    Deschner, Benjamin W.
    Dickson, Paxton V.
    Deneve, Jeremiah L.
    Glazer, Evan S.
    Yakoub, Danny
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : S268 - S268
  • [7] Recurrence risk factors for advanced gastric cancer after D2 gastrectomy followed by adjuvant chemotherapy
    Hwang, Jun-Eul
    Kim, Min-Jee
    Shim, Hyun-Jeong
    Bae, Woo-Kyun
    Cho, Sang-Hee
    Chung, Ik-Joo
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [8] Prolonged adjuvant capecitabine chemotherapy improved survival of stage IIIA gastric cancer after D2 gastrectomy
    Feng, Wen Ming
    Tang, Cheng Wu
    Guo, Hui Hui
    Bao, Ying
    Fei, Mao Yun
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2015, 72 : 140 - 143
  • [9] Indications for Adjuvant Chemotherapy in Stage II Gastric Cancer After D2 Gastrectomy–A Chinese Multicenter Study
    Zi-Jian Deng
    Jun Lu
    Run-Cong Nie
    Jia-Ming Fang
    Xi-Jie Chen
    Jun-Jie Liu
    Xian-Zhe Li
    Ying-Bo Chen
    Chang-Ming Huang
    Lei Lian
    Jun-Sheng Peng
    Shi Chen
    [J]. Annals of Surgical Oncology, 2022, 29 : 8214 - 8224
  • [10] Impact of D2 Gastrectomy for Locally Advanced Gastric Cancer in the Era of Effective Adjuvant Chemotherapy
    Yukinori Yamagata
    Takaki Yoshikawa
    Kenichi Ishizu
    Mai Tsutsui
    Takeyuki Wada
    Tsutomu Hayashi
    [J]. World Journal of Surgery, 2023, 47 : 1512 - 1518